Get started
Author

Sarah Kelly

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020 · Katie J. Ewer, Jordan R. Barrett, et al. · Nature Medicine · 587
PDF
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020 · Jordan R. Barrett, Sandra Belij-Rammerstorfer, et al. · Nature Medicine · 315
PDF
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021 · Amy Flaxman, Natalie G Marchevsky, et al. · The Lancet · 235
PDF
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial
2021 · Firdausi Qadri, Farhana Khanam, et al. · The Lancet · 152
PDF
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial
2021 · Mila Shakya, Merryn Voysey, et al. · The Lancet Global Health · 105
PDF
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
2013 · Matthew D. Snape, Praveen Saroey, et al. · Canadian Medical Association Journal · 85
PDF
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
2021 · Sue Ann Costa Clemens, Pedro M. Folegatti, et al. · Nature Communications · 57
PDF
Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses
2013 · Matthew D. Snape, John Philip, et al. · The Pediatric Infectious Disease Journal · 43
Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age
2014 · Fiona McQuaid, Matthew D. Snape, et al. · The Pediatric Infectious Disease Journal · 38
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial
2024 · Firdausi Qadri, Farhana Khanam, et al. · The Lancet · 37
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months
2015 · Fiona McQuaid, Matthew D. Snape, et al. · Canadian Medical Association Journal · 37
PDF
A Cross-Sectional Observational Study of Pneumococcal Carriage in Children, Their Parents, and Older Adults Following the Introduction of the 7-Valent Pneumococcal Conjugate Vaccine
2015 · Mainga Hamaluba, Rama Kandasamy, et al. · Medicine · 37
Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial
2015 · Mainga Hamaluba, Rama Kandasamy, et al. · The Lancet Infectious Diseases · 21
PDF
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh
2023 · Farhana Khanam, Golap Babu, et al. · Vaccine · 18
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study
2022 · Shrijana Shrestha, Meeru Gurung, et al. · The Lancet Global Health · 18
PDF
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
2022 · Natalie Gabrielle Marchevsky, Grace Li, et al. · EBioMedicine · 17
Streptococcus pneumoniae Carriage Prevalence in Nepal: Evaluation of a Method for Delayed Transport of Samples from Remote Regions and Implications for Vaccine Implementation
2014 · Sarah Hanieh, Mainga Hamaluba, et al. · PLoS ONE · 15
PDF
Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C)
2024 · Evangelos Bellos, Dilys Santillo, et al. · The Journal of Experimental Medicine · 14
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2021 · Jordan R. Barrett, Sandra Belij-Rammerstorfer, et al. · Nature Medicine · 13
PDF
Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial
2019 · Rama Kandasamy, Meeru Gurung, et al. · The Lancet Infectious Diseases · 10
PDF
Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine
2018 · Johannes Trück, Sarah Kelly, et al. · The Pediatric Infectious Disease Journal · 9
PDF
Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal
2019 · Rachel Colin-Jones, Mila Shakya, et al. · Clinical Infectious Diseases · 8
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2021 · Katie J. Ewer, Jordan R. Barrett, et al. · Nature Medicine · 7
PDF
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials
2023 · Sarah Kelly, Xinxue Liu, et al. · Trials · 4
PDF
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
2023 · Sue Ann Costa Clemens, Natalie Marchevsky, et al. · Human Vaccines & Immunotherapeutics · 4
PDF
Works count: 42
Citation count: 1,898
H-index: 16
I10-index: 20
Year
Topic
Type